Compounds > recoflavone
Page last updated: 2024-11-12

recoflavone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID9952125
CHEMBL ID4297606
SCHEMBL ID2483541
MeSH IDM0336723

Synonyms (26)

Synonym
recoflavone [inn]
recoflavone
u96j5lg435 ,
203191-10-0
da 6034
unii-u96j5lg435
acetic acid, ((2-(3,4-dimethoxyphenyl)-5-methoxy-4-oxo-4h-1-benzopyran-7-yl)oxy)-
7-(carboxymethyloxy)-3',4',5-trimethoxyflavone
da-6034
7-carboxymethoxyloxy-3',4',5-trimethoxyflavone
acetic acid, 2-((2-(3,4-dimethoxyphenyl)-5-methoxy-4-oxo-4h-1-benzopyran-7-yl)oxy)-
((2-(3,4-dimethoxyphenyl)-5-methoxy-4-oxo-4h-chromen-7-yl)oxy)acetic acid
SCHEMBL2483541
DTXSID50174205
2-[2-(3,4-dimethoxyphenyl)-5-methoxy-4-oxochromen-7-yl]oxyacetic acid
da-60342
DB12058
2-((2-(3,4-dimethoxyphenyl)-5-methoxy-4-oxo-4h-chromen-7-yl)oxy)acetic acid
acetic acid, 2-[[2-(3,4-dimethoxyphenyl)-5-methoxy-4-oxo-4h-1-benzopyran-7-yl]oxy]-
SB18971
da6034
Q27290945
CHEMBL4297606
HY-106449
CS-0025847
AKOS040753717

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" Twenty-two mild adverse events were reported in 14 subjects."( Pharmacokinetics, safety and tolerability of DA-6034, an anti-inflammatory agent, after single and multiple oral administrations in healthy volunteers.
Chung, JY; Jang, IJ; Kim, JR; Lee, J; Lim, KS; Shin, KH, 2014)		0.4

Pharmacokinetics

ExcerptReferenceRelevance
" After oral administration, the pharmacokinetic parameters of DA-6034 were not significantly different between male and female rats."( Gender differences in the pharmacokinetics of DA-6034, a derivative of flavonoids, in rats.
Bae, SK; Kwon, JW; Lee, MG; Yang, SH; Yoo, M, 2006)		0.33
" Pharmacokinetic parameters of DA-6034 after intravenous and oral administration at various doses were dose-independent in dogs."( Pharmacokinetics of DA-6034, an agent for inflammatory bowel disease, in rats and dogs: Contribution of intestinal first-pass effect to low bioavailability in rats.
Choi, HD; Choi, YH; Chung, HJ; Jang, JM; Kwon, JW; Lee, MG; Shim, HJ; Yoo, M, 2006)		0.33
" Serial blood and urine samples were taken for pharmacokinetic analysis."( Pharmacokinetics, safety and tolerability of DA-6034, an anti-inflammatory agent, after single and multiple oral administrations in healthy volunteers.
Chung, JY; Jang, IJ; Kim, JR; Lee, J; Lim, KS; Shin, KH, 2014)		0.4
"DA-6034 had minimal absorption, and the pharmacokinetic parameters were highly variable among subjects."( Pharmacokinetics, safety and tolerability of DA-6034, an anti-inflammatory agent, after single and multiple oral administrations in healthy volunteers.
Chung, JY; Jang, IJ; Kim, JR; Lee, J; Lim, KS; Shin, KH, 2014)		0.4

Dosage Studied

ExcerptRelevanceReference
" For both the single- and multiple-dose administrations, the coefficients of variation of the area under the plasma concentration-time curve to the last observation (AUClast) and the area under the plasma concentration-time curve over the dosing interval at steady state (AUCss,τ) ranged from 16."( Pharmacokinetics, safety and tolerability of DA-6034, an anti-inflammatory agent, after single and multiple oral administrations in healthy volunteers.
Chung, JY; Jang, IJ; Kim, JR; Lee, J; Lim, KS; Shin, KH, 2014)		0.4
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (16)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's1 (6.25)18.2507
2000's9 (56.25)29.6817
2010's6 (37.50)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 23.02

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index23.02 (24.57)
Research Supply Index2.94 (2.92)
Research Growth Index5.38 (4.65)
Search Engine Demand Index21.17 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (23.02)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (5.88%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other16 (94.12%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
acetic acid
Acetic Acid: Product of the oxidation of ethanol and of the destructive distillation of wood. It is used locally, occasionally internally, as a counterirritant and also as a reagent. (Stedman, 26th ed). acetic acid : A simple monocarboxylic acid containing two carbons.		2.4220monocarboxylic acidantimicrobial food preservative;
Daphnia magna metabolite;
food acidity regulator;
protic solvent
aspirin
Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5). acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.. acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.		2.0310benzoic acids;
phenyl acetates;
salicylates		anticoagulant;
antipyretic;
cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor;
drug allergen;
EC 1.1.1.188 (prostaglandin-F synthase) inhibitor;
geroprotector;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
plant activator;
platelet aggregation inhibitor;
prostaglandin antagonist;
teratogenic agent
indomethacin
Indomethacin: A non-steroidal anti-inflammatory agent (NSAID) that inhibits CYCLOOXYGENASE, which is necessary for the formation of PROSTAGLANDINS and other AUTACOIDS. It also inhibits the motility of POLYMORPHONUCLEAR LEUKOCYTES.. indometacin : A member of the class of indole-3-acetic acids that is indole-3-acetic acid in which the indole ring is substituted at positions 1, 2 and 5 by p-chlorobenzoyl, methyl, and methoxy groups, respectively. A non-steroidal anti-inflammatory drug, it is used in the treatment of musculoskeletal and joint disorders including osteoarthritis, rheumatoid arthritis, gout, bursitis and tendinitis.		2.4720aromatic ether;
indole-3-acetic acids;
monochlorobenzenes;
N-acylindole		analgesic;
drug metabolite;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
environmental contaminant;
gout suppressant;
non-steroidal anti-inflammatory drug;
xenobiotic metabolite;
xenobiotic
sulfasalazine
Sulfasalazine: A drug that is used in the management of inflammatory bowel diseases. Its activity is generally considered to lie in its metabolic breakdown product, 5-aminosalicylic acid (see MESALAMINE) released in the colon. (From Martindale, The Extra Pharmacopoeia, 30th ed, p907). sulfasalazine : An azobenzene consisting of diphenyldiazene having a carboxy substituent at the 4-position, a hydroxy substituent at the 3-position and a 2-pyridylaminosulphonyl substituent at the 4'-position.		210
prednisolone
Prednisolone: A glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states.. prednisolone : A glucocorticoid that is prednisone in which the oxo group at position 11 has been reduced to the corresponding beta-hydroxy group. It is a drug metabolite of prednisone.		21011beta-hydroxy steroid;
17alpha-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(1),Delta(4)-steroid;
C21-steroid;
glucocorticoid;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone		adrenergic agent;
anti-inflammatory drug;
antineoplastic agent;
drug metabolite;
environmental contaminant;
immunosuppressive agent;
xenobiotic
trinitrobenzenesulfonic acid
Trinitrobenzenesulfonic Acid: A reagent that is used to neutralize peptide terminal amino groups.. 2,4,6-trinitrobenzenesulfonic acid : The arenesulfonic acid that is benzenesulfonic acid with three nitro substituents in the 2-, 4- and 6-positions.		2.4220arenesulfonic acid;
C-nitro compound		epitope;
explosive;
reagent
atropine
tropan-3alpha-yl 3-hydroxy-2-phenylpropanoate : A tropane alkaloid that is (1R,5)-8-methyl-8-azabicyclo[3.2.1]octane substituted by a (3-hydroxy-2-phenylpropanoyl)oxy group at position 3.		2.0510
oxazolone
Oxazolone: Immunologic adjuvant and sensitizing agent.		2.0310
dinoprostone
prostaglandin E2 : Prostaglandin F2alpha in which the hydroxy group at position 9 has been oxidised to the corresponding ketone. Prostaglandin E2 is the most common and most biologically potent of mammalian prostaglandins.		2.0310prostaglandins Ehuman metabolite;
mouse metabolite;
oxytocic
scopolamine hydrobromide
[no description available]		2.0510
interleukin-8
Interleukin-8: A member of the CXC chemokine family that plays a role in the regulation of the acute inflammatory response. It is secreted by variety of cell types and induces CHEMOTAXIS of NEUTROPHILS and other inflammatory cells.		2.0610
ConditionIndicatedRelationship StrengthStudiesTrials
Disease Models, Animal
Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.		03.1550
Enteritis
Inflammation of any segment of the SMALL INTESTINE.		02.1310
Dry Eye
[description not available]		02.4620
Dry Eye Syndromes
Corneal and conjunctival dryness due to deficient tear production, predominantly in menopausal and post-menopausal women. Filamentary keratitis or erosion of the conjunctival and corneal epithelium may be caused by these disorders. Sensation of the presence of a foreign body in the eye and burning of the eyes may occur.		14.4620
Dehydration
The condition that results from excessive loss of water from a living organism.		02.0510
Dacryoadenitis
[description not available]		02.0510
Bowel Diseases, Inflammatory
[description not available]		02.7130
Inflammatory Bowel Diseases
Chronic, non-specific inflammation of the GASTROINTESTINAL TRACT. Etiology may be genetic or environmental. This term includes CROHN DISEASE and ULCERATIVE COLITIS.		02.7130
Gastric Ulcer
[description not available]		02.0310
Stomach Ulcer
Ulceration of the GASTRIC MUCOSA due to contact with GASTRIC JUICE. It is often associated with HELICOBACTER PYLORI infection or consumption of nonsteroidal anti-inflammatory drugs (NSAIDS).		02.0310
Body Weight
The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.		02.0410
Cell Transformation, Neoplastic
Cell changes manifested by escape from control mechanisms, increased growth potential, alterations in the cell surface, karyotypic abnormalities, morphological and biochemical deviations from the norm, and other attributes conferring the ability to invade, metastasize, and kill.		02.0410
Cancer of Colon
[description not available]		02.0410
Acute Disease
Disease having a short and relatively severe course.		02.0410
Colitis
Inflammation of the COLON section of the large intestine (INTESTINE, LARGE), usually with symptoms such as DIARRHEA (often with blood and mucus), ABDOMINAL PAIN, and FEVER.		02.4220
Colonic Neoplasms
Tumors or cancer of the COLON.		02.0410
Gastritis
Inflammation of the GASTRIC MUCOSA, a lesion observed in a number of unrelated disorders.		14.0410
Weight Reduction
[description not available]		0210
Weight Loss
Decrease in existing BODY WEIGHT.		0210